Nanobiotix

Nanobiotix placed 2,218,467 common shares (including ADS) plus 345,099 pre-funded warrants following full exercise of the overallotment option and raised gross proceeds of about 100 million US dollars. The subscription price was €33.60 per common share ($38.98 per ADS) and represented a 14.92% discount to the volume-weighted average price. Net proceeds are intended to finance <10% the development of JNJ-1900 (NBTXR3), 50–60% the Nanoprimer and other platforms, and 30–40% general corporate purposes; the company expects that, together with existing cash, this will cover funding needs through 2029. Given a current market capitalization of $16.67 million, the transaction leads to significant dilution for existing shareholders. » More on de.investing.com

Jefferies raised its price target for Nanobiotix from €21.50 to €60.00, citing reduced risks following positive study data for NBTXR3 in non‑small cell lung cancer. The stock climbed intraday by as much as 11.58% to €37.40, thereby holding its 21‑day moving average after a recent pullback. Analyst Shan Hama also praised a capital increase that secures the company’s financing through 2029. » More on finanzen.net

The FDA has approved a protocol amendment for the global Phase 3 study NANORAY-312, submitted by sponsor Johnson & Johnson, which removes a planned interim analysis. The final analysis will be adjusted to require fewer events; the readout is expected to occur in a similar timeframe as the originally planned interim analysis. The agent JNJ-1900 (NBTXR3) will continue to be evaluated in locally advanced squamous cell carcinomas of the head and neck; under its license agreement with Janssen, Nanobiotix may be eligible for future milestone payments. » More on de.investing.com

Nanobiotix posted a net loss of €24 million for fiscal 2025, down from €68.1 million in 2024, driven by a revised license agreement with Johnson & Johnson and a 43% reduction in R&D spending. Revenue rose to €32.6 million but included a one-off accounting effect. EPS was -0.5069, missing expectations, and the stock reacted positively in pre-market trading. The company expects further benefits from milestone payments and sees liquidity through early 2028. » More on de.investing.com

Nanobiotix shares rose 11.6% after promising initial data from a phase‑1 study of JNJ‑1900 (NBTXR3) in locally advanced esophageal adenocarcinoma. In 13 patients the study confirmed the technical feasibility of intratumoral injection and good tolerability; the disease control rate was 85% and the objective response rate 69% (six complete, three partial remissions). The recommended phase‑2 dose in combination with photon chemo‑radiotherapy was set at 33% of the gross tumor volume, and recruitment for additional cohorts is ongoing. » More on de.investing.com